Evidence map›Paper›PMID 37397644›Full record

ArticleCureus2023

Immunohistochemical Expression of Ki-67, Dopamine D1 and Dopamine D2 Receptors in Meningiomas in a Tertiary Institution in Mexico.

Luis A Rodríguez-Hernández, Jorge Navarro-Bonnet, Alma Ortiz-Plata, Juan P Gonzalez-Mosqueda, Pablo Martinez-Arellano, Metztli Calva-González, Marcos V Sangrador-Deitos, Michel G Mondragón-Soto, Diego Lopez Mena, Lesly Portocarrero-Ortiz

Abstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luis A Rodríguez-HernándezNeurological Surgery, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MEX.
Jorge Navarro-BonnetNeurological Surgery, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, Mexico City, MEX.
Alma Ortiz-PlataNeuropathology, Instituto Nacional de Neurologia y Neurocirugía Manuel Velasco Suarez, Mexico City, MEX.
Juan P Gonzalez-MosquedaNeurological Surgery, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, Mexico City, MEX.
Pablo Martinez-ArellanoNeurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, Mexico City, MEX.
Metztli Calva-GonzálezPsychiatry, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MEX.
Marcos V Sangrador-DeitosNeurological Surgery, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MEX.
Michel G Mondragón-SotoNeurological Surgery, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MEX.
Diego Lopez MenaNeurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez, Mexico City, MEX.
Lesly Portocarrero-OrtizNeuroendocrinology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives Meningiomas (MNGs) are the most common intracranial tumors found in the adult population. While most intracranial MNGs may be surgically removed, a subset of patients remains ineligible for conventional treatment. This is either because of a lack of surgical access or due to atypical, anaplastic or invasive characteristics of the tumors. These patients may benefit from targeted therapies that focus on cell receptor expression. The aim of this study was to assess dopamine receptor (DR) and Ki-67 expression in the MGNs of patients treated with surgery in the Instituto Nacional de Neurología y Neurocirugía, Mexico. Materials and methods This study analyzed 23 patients with confirmed MNG diagnoses (10 female and 13 male (mean age: 44.5 years)) who had undergone surgical resection between 2010 and 2014 at our institution. In the collected samples, we performed analyses for Ki-67, Dopamine 1 and Dopamine 2 receptors' expression. Results For the markers Ki-67, DR-D1 and DR-D2, the mean percentual expressions were 18.9%, 23.02% and 8.33%. No significant correlation was found between the expressions of these receptors and the studied MNG characteristics. The expression index of Ki-67 showed a significant relation with mean age (p = 0.03) and prolactin levels (p = 0.02). Conclusions Samples showed varied expressions of the studied receptors. Despite the difference in expressions between the markers, more studies are needed to confirm the findings. In contrast to previous studies, we could not find any relationship between D2-R and tumor characteristics.

Indexed as

atypical meningiomascancerd2 receptorsdopamine receptorski-67 expression

Identifiers

PMID37397644
PMCPMC10314723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.